BMO Capital Positive on Abbvie (ABBV) Humira Win Versus Amgen (AMGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
AbbVie (ABBV) Taps Session High
January 15, 2016 10:32 AM ESTAbbVie (NYSE: ABBV) advanced to session highs Friday morning, rising 3.3%.
Amgen (AMGN) Rejected in Challenges to Abbvie (ABBV) Patents on Humira - Bloomberg
January 14, 2016 3:58 PM ESTAmgen (NASDAQ: AMGN) Rejected in Challenges to Abbvie (NYSE: ABBV) Patents on Humira - Bloomberg
... MoreUPDATE: AbbVie (ABBV) Pops on Amgen-Related IPR Patent Chatter
January 14, 2016 3:43 PM EST(Updated - January 14, 2016 3:49 PM EST)
AbbVie (NYSE: ABBV) pops to session highs.
UPDATE - AbbVie is said to be gaining on denial of Amgen's (Nasdaq: AMGN) IPR patent reexaminations covering the '157 and '158 patents, according to market chatter.
Shares of AbbVie rose as much as 11 percent on Thursday's session.
... More